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Purpose: Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor indicated for 
the reduction of thrombotic cardiovascular events in patients with coronary artery disease 
(CAD) undergoing percutaneous coronary intervention (PCI) in whom oral P2Y12 inhibitors 
are not feasible or desirable. The objective was to assess the financial impact of introducing 
cangrelor into the hospital formulary in Spain.
Patients and Methods: A budget impact model was developed to calculate the cost 
difference between two scenarios (without and with cangrelor) to treat CAD patients under-
going PCI in whom oral P2Y12 inhibitors are not feasible or desirable, over 3 years. 
Intravenous P2Y12 inhibitor (cangrelor), oral P2Y12 inhibitors (clopidogrel, prasugrel, and 
ticagrelor), and glycoprotein IIb-IIIa inhibitors (GPIs) for bail-out use were considered. 
Epidemiological, efficacy (thrombotic events including cardiac death), safety (bleeding 
events), and costs (€, 2019) data were based on Spanish registries, clinical trials, and meta- 
analyses. One-way sensitivity analysis established the effect of uncertainty on results.
Results: For years 1, 2, and 3, the target population to receive cangrelor was 607, 1,822, 
and 3,340 patients, and cangrelor uptake was 23.70%, 58.30%, and 51.30%, respectively. 
The 3-year budget impact was 1,021,717€ varying from 50,245€ in year 1 to 599,272€ 
in year 3. The results were sensitive to the number of patients treated with GPIs in Spanish 
hospitals.
Conclusion: Based on our results, the financial effort needed to introduce the use of 
cangrelor in patients undergoing PCI in whom antiplatelet therapy with oral P2Y12 inhibitors 
is not feasible or desirable barely exceeds one million € over three years, in Spain.
Keywords: P2Y12 inhibitors, cangrelor, percutaneous coronary intervention, budget impact
Introduction
In Spain, acute coronary syndromes (ACS), including ST elevation myocardial 
infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and 
unstable angina are the leading cause of morbidity and mortality, and of elevated 
healthcare costs.1 Percutaneous coronary intervention (PCI) is the recommended 
reperfusion strategy for both STEMI (primary PCI) and high-risk NSTEMI 
patients.2 In 2018, 72,520 PCIs were performed in 109 hospitals in Spain; 21,261 
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were done in acute myocardial infarction (91% primary 
PCI), exceeding the estimates of 400 primary PCIs 
per million population.3
Platelet inhibition is a key component of the peripro-
cedural adjunctive therapy.4,5 Oral P2Y12 inhibitors (clo-
pidogrel, prasugrel, or ticagrelor) with concomitant 
acetylsalicylic acid (ASA) are the standard of care.6 
However, and despite the significant advances made in 
the use of adjunctive antiplatelet treatment and in the 
PCI procedure, 12% of STEMI and 4.3% of NSTEMI 
patients remain at risk for periprocedural thrombotic com-
plications (including myocardial infarction and stent 
thrombosis), as well as at risk for major bleedings.7–10 In 
2018, the budget impact of treating patients with ACS 
undergoing PCI with oral prasugrel, ticagrelor, or clopido-
grel was calculated to reach 76 million € in Spain.11 
Pharmacy, myocardial infarction, urgent revascularization, 
minor and major bleeding, and stroke were the major cost 
components.11 In patients with ACS presenting with car-
diogenic shock (5–10% of STEMI and 2–3% of 
NSTEMI12,13), or with active vomiting (30% of STEMI 
patients14) in whom treatment with oral P2Y12 inhibitors 
may not be feasible, glycoprotein IIb-IIIa inhibitors (GPIs) 
are parenteral options.10,15 However, GPIs are recom-
mended for bail-out use only, provided their narrow ther-
apeutic window.4,5
Cangrelor is an intravenous (iv) P2Y12 receptor inhi-
bitor that prevents adenosine diphosphate (ADP) signal-
ing and platelet activation in a direct and reversible way 
within two minutes of administering a bolus followed by 
continuous infusion. The antiplatelet effect is consistently 
maintained along the duration of the infusion, and platelet 
function returns to normal within one hour following the 
cessation of it.16–18 Co-administered with ASA, cangrelor 
is indicated for the reduction of thrombotic cardiovascu-
lar events in adults with coronary disease undergoing PCI 
who have not received an oral P2Y12 inhibitor prior to the 
PCI procedure and in whom oral therapy with P2Y12 
inhibitors is not feasible or desirable.18 The pooled ana-
lysis of 3 pivotal trials (CHAMPION program)7,19,20 
evaluating the efficacy and safety of cangrelor vs clopi-
dogrel reported that cangrelor significantly reduced the 
odds of the primary efficacy composite of all-cause death, 
myocardial infarction, ischemia-driven revascularization, 
or stent thrombosis at 48 h by 19% (p = 0.0007 vs 
clopidogrel), and stent thrombosis (key secondary end-
point) by 41% (p = 0.0008).18 As it might be expected for 
a potent and immediate antiplatelet strategy, cangrelor 
increased periprocedural GUSTO mild bleeding events 
(16.8% vs 13.0%, cangrelor vs clopidogrel; 
p<0.0001).18 Based on the evidence on the efficacy and 
safety of cangrelor provided by the CHAMPION 
program,7,18–20 the ESC guidelines recommend that can-
grelor may be considered as an iv option to achieve an 
immediate inhibition of the ADP-induced platelet aggre-
gation after iv bolus plus perfusion, and to allow the 
restoration of the normal platelet function within 1 
h after the cessation of the perfusion.4,5
This study was undertaken to assess the financial 
impact of introducing cangrelor into the drug formulary 
of hospital pharmacies in Spain as adjunctive treatment to 
reduce the risk of periprocedural thrombotic events in 
candidate patients for PCI, in whom antiplatelet therapy 
with oral P2Y12 inhibitors is not feasible or desirable.
Patients and Methods
Budget Impact Model
A budget impact model was built in Excel for Microsoft® 
to calculate the difference in costs of two hypothetical 
scenarios from the perspective of the National Health 
System, over a three-year time horizon (2019–2021), in 
Spain:
1. Current scenario, without cangrelor assuming 
patients receive antiplatelet treatment with oral P2Y12 
inhibitors (pre-treatment) or GPIs (bail-out).
2. Alternative scenario, with cangrelor assuming 
patients receive oral P2Y12 inhibitors (pre-treatment) or 
cangrelor or GPIs (bail-out).
Inputs and Data Sources
First, a conceptual budget impact model was defined to set 
the appropriate PCI scenarios to be compared. Second, the 
medical literature and diverse sources of pharmacoeco-
nomic information were reviewed to identify the most 
relevant and consistent data which may reflect as best as 
possible usual clinical practice in Spain. The pivotal clin-
ical trial of cangrelor was used to estimate the efficacy and 
safety of cangrelor compared with clopidogrel;18 in the 
absence of indirect comparisons, a meta-analysis was uti-
lized to calculate the efficacy and safety of cangrelor 
compared with prasugrel and ticagrelor;21 Spanish inter-
ventional cardiology registries were searched to identify 
population data and typical use of GPIs;22–24 market 
research information was gathered to infer market share 
over three years.
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Third, assumptions were made to solve data inconsis-
tencies, and the opinion of clinical experts was sought for 
validation. Three interventional cardiologists working for 
more than ten years in reference PCI Cath-Labs in Spain 
gave their expert opinion and validated sources, inputs, 
assumptions, and calculations. For validation, a semi- 
structured questionnaire was distributed by email. 
Experts were asked to choose the most appropriate group 
of data from the entire set extracted from the literature. In 
case of discrepancies, an external expert was required for 
the final decision.
The model was finally nourished with a set of endorsed 
epidemiological, clinical, and direct healthcare costs data, 
as follows (Tables 1–3):
1. Epidemiological data: total PCI population3,22,23 pri-
mary PCI population23,25 and population of PCI patients in 
whom the use of oral P2Y12 inhibitors is not feasible or 
desirable.13,26,27
2. Clinical data: diagnosis at entry (STEMI, NSTEMI, 
stable CAD and other, that included any cardiovascular 
event that according to the criteria of the responsible 
physician deserved a PCI);11,23 pharmacological treatment 
(before and during PCI);11,18,22,28,29 risk of ischemic and 
bleeding events with each antiplatelet strategy.18,21
3. Direct healthcare costs data: ischemic and bleeding 
events unitary costs;30 drugs unitary costs.31
The size, growth, and percentage distribution (primary 
PCI/total PCI) of the PCI population were estimated from 
the Spanish registry of interventional cardiology for the 
2016 to 2018 period.3,22,23,25 A 2% steady growth of the 
total PCI population over the three years of analysis was 
assumed.
In a face-to-face interaction, the clinical experts vali-
dated the final version of the model and the budget impact 
results.
Target Population
The target population included STEMI and NSTEMI 
patients candidate for PCI, in whom antiplatelet therapy 
with oral P2Y12 inhibitors was not feasible or 
desirable.12–14 Its size was derived from the total PCI 
population in Spain (74,217 individuals in year 1, 75,978 
in year 2, and 77,768 in year 3) (Table 1).3,22,23
The percentage of patients in whom antiplatelet ther-
apy with oral P2Y12 inhibitors was not feasible or desir-
able was based on data from the national registry of 
interventional cardiology on the 2016 to 2018 period 
and PCI population growth, on the estimated incidence 
of cardiogenic shock in PCI candidates, and on the 
opinion of clinical experts on drugs usage. It was calcu-
lated in 1.02% of the total PCI population in year 1, and 
to grow to 5.37% in year 313,26,27 (Table 1). It reached 
a total of 7,220 patients over three years (Figure 1). It 
was forecasted that adjuvant antiplatelet treatment with 
oral P2Y12 inhibitors would be needed in 607, 1,822, 
and 3,340 of these patients, respectively. They totalized 
5,769 patients over three years (Table 1).
Table 1 Size and Distribution of the PCI Population in Spain Over Three Years
Year 1 Year 2 Year 3 References
Population size
Total PCI, n 74,217 75,978 77,768 22,23
STEMI/Primary PCI population, % 100% 100% 100% KOL
Primary/Total PCI, % 25% 25% 25% 23,25
Total PCI population in whom oral P2Y12 inhibitors are not feasible or desirable/Total PCI population, % 1.02% 3.00% 5.37%
13,26,27
Total population in whom oral P2Y12 inhibitors are not feasible or desirable, n 760 2,280 4,180
Three-years total population in whom oral P2Y12 inhibitors are not feasible or desirable, n 7,220
Patients in whom antiplatelet treatment with oral P2Y12 inhibitors would be needed, n 607 1,822 3,340
Three-years population in whom antiplatelet treatment with oral P2Y12 inhibitors would be needed, n 5,769
Population diagnosis
ST-elevation myocardial infarction (STEMI) 30% 30% 30% 11,23
Non-ST-elevation myocardial infarction (NSTEMI) 40% 40% 40%
Stable coronary artery disease (SCAD) 22% 22% 22%
Others 8% 8% 8%
Abbreviations: KOL, key opinion leader; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
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Use of Antiplatelet Therapy in the PCI 
Population
In the scenario without cangrelor in the hospital formulary, 
it was considered that 80% of the PCI patients received 
oral P2Y12 inhibitors (pre-treatment) and 6.50% of the 
patients received GPIs (bail-out), based on data taken 
from national registries,24 the literature,11 and on the opi-
nion of clinical experts (Table 2).
In the scenario with cangrelor in the hospital formulary, the 
population receiving P2Y12 inhibitors was distributed amongst 
those receiving oral P2Y12 inhibitors and those receiving 
cangrelor. The proportion of patients in whom the use of oral 
P2Y12 inhibitors would not be feasible or desirable and could 
therefore be treated with cangrelor was 23.70% in year 1, 
58.30% in year 2, and 51.30% in year 3 of the total PCI 
population (Table 2). The proportion of patients treated with 
GPIs (bail-out) slightly decreased with cangrelor in the hospi-
tal formulary, based on the opinion of clinical experts.
Clinical Outcomes
Periprocedural clinical outcomes (up to 48h of PCI) were 
ischemic events (stent thrombosis, myocardial infarction, 
Table 2 Distribution (in Percentage) of the Use of GPIs and Oral P2Y12 Inhibitors without and with Cangrelor in the Hospital 
Formulary in the PCI Population in Spain
Percentage Usage References
Year 1 Year 2 Year 3
Pharmacological treatment current scenario (without cangrelor)*
Proportion of patients with oral P2Y12 inhibitors, % 80% 80% 80%
11,28 and KOL
Clopidogrel, % 18.20% 18.20% 18.20% Estimated from28
Prasugrel, % 9.10% 9.10% 9.10%
Ticagrelor, % 72.70% 72.70% 72.70%
Proportion of patients on GPIs (bail-out), % 6.5% 6.5% 6.5% Estimated from22
Abciximab, % 93% 93% 93% Estimated from22
Eptifibatide, % 3% 3% 3%
Tirofiban, % 4% 4% 4%
Pharmacological treatment alternative scenario (with cangrelor)
Proportion of patients with oral P2Y12 inhibitors and cangrelor, % 80% 80% 80%
11,28
Clopidogrel, % 17.50% 16.90% 16.80% Use forecast
Prasugrel, % 9.00% 9.00% 9.00% Use forecast
Ticagrelor, % 49.80% 15.80% 22.90% Use forecast
Cangrelor, % 23.70% 58.30% 51.30% Use forecast
Proportion of patients on GPIs (bail-out), % 6.3% 6.3% 6.3% Estimated from18 and KOL
Abciximab, % 93% 93% 93% Estimated from22
Eptifibatide, % 3% 3% 3%
Tirofiban, % 4% 4% 4%
Notes: *The current scenario is a scenario without cangrelor in the market; it reflects current practice, and it would be the same from year 1 to 3 in the model (assumption). 
Abbreviations: GPIs, glycoprotein IIb-IIIa inhibitors; KOL, key opinion leader; PCI, percutaneous coronary intervention.
Table 3 Efficacy and Safety Outcome Rates of P2Y12 Inhibitors in the PCI Population in Spain
P2Y12 Inhibitor Efficacy Outcomes at 48 Hours of PCI Safety Outcomes, TIMI, at 48 Hours of PCI References
ST MI IDR Cardiac Death Major Minor
Clopidogrel 0.85% 3.65% 0.74% 0.36% 0.22% 0.41% 18
Prasugrel 0.42% 2.77% 0.59% 0.36% 0.65% 0.44% Estimated from21
Ticagrelor 0.57% 2.74% 0.62% 0.34% 0.25% 0.65%
Cangrelor 0.50% 3.11% 0.53% 0.26% 0.25% 0.61% 18
Abbreviations: IDR, ischemia-driven revascularization; MI, myocardial infarction; PCI, percutaneous coronary intervention; ST, stent thrombosis; TIMI, thrombolysis in 
myocardial infarction bleeding classification.
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ischemia-driven revascularization, cardiac death) (efficacy),18 
and major and minor bleeding events according to the 
Thrombolysis in Myocardial Infarction (TIMI) criteria21 
(safety) with P2Y12 inhibitors (Table 3). The pooled analysis 
of the CHAMPION PROGRAM published by Steg et al 
(2013)18 that compared cangrelor to clopidogrel and the net-
work metanalysis by Westman et al (2017)21 that allowed to 
compare cangrelor, ticagrelor, and prasugrel to clopidogrel 
were used to derive ischemic and bleeding data.
Costs Data
Costs data are shown in supplementary Table 1. 
Pharmacological costs included P2Y12 inhibitors and 
GPIs (bail-out) and were driven from official 
databases.31 A 7.5% discount was applied to the cost of 
ticagrelor and cangrelor, and a 15% discount was con-
sidered for abciximab and eptifibatide following national 
drug price regulations (Real Decreto Ley (RDL) 8/ 
2010).32 No discounts were applied to generic antiplatelet 
drugs. Clinical events costs were estimated from the 
literature.30
Costs were updated to 2019 € based on the Consumer 
Price Index (CPI) percentage changes for Spain33 and it 
was assumed that they would remain unchanged from 
2020 onwards.
Assumptions
Assumptions were made when data were unavailable or 
inconsistent. They are summarized in Table 4. 
Assumptions were validated by clinical experts to better 
represent the usual clinical practice in Spain.
Sensitivity Analysis
A one-way sensitivity analysis was conducted to assess the 
impact of different parameters on the budget impact 
results. The parameters included in the sensitivity analysis 
were suggested by the clinical experts. Percentage use of 
GPIs [current scenario: mean, 6.50% (range: 3.00% - 
12.70%); alternative scenario: mean, 6.35% (range: 
2.60% - 12.40%)]; percentage use of generic clopidogrel 
[mean: 62% (range: 50% - 100%)]; and costs of clinical 
events (±20%) were considered to highly influence budget 
impact according to usual practice in Spain.18,25.
Ethical Considerations
This was a pharmacoeconomic, non-interventional study, 
based on the collection of data from the literature and from 
public health reports and registries without involvement of 
human subjects. Ethical approval was not required to conduct 
this study.
Results
In the base case scenario, PCI patients in whom oral P2Y12 
inhibitors are not feasible or desirable reaches 7,220 over 
three years (Figure 1); 5,769 patients would benefit from 
cangrelor as shown in Tables 1 and 2 and would benefit 
from achieving the corresponding efficacy and safety out-
comes as described in Table 3. In this scenario, it was 
calculated that adding cangrelor at a tentative ex-factory 
price of 336.70€ per vial (legal VAT and a 7.5% mandatory 
discount included) into the hospital formulary, for the acute 
care of PCI patients in whom the antiplatelet therapy with 
oral P2Y12 inhibitors is not feasible or desirable would 
represent 1,021,717€ over 3 years, in Spain (Table 5). The 
budget impact would be 50,245€ in year one, 372,200€ 
in year two, and 599,272€ in year three.
The introduction of cangrelor would modify the costs 
associated with the use of P2Y12 inhibitors in the hospital 
(Figure 2). It may increase the hospital pharmacy costs 
associated to the use of P2Y12 inhibitors totalizing 976,802 
€ over three years. Patients will remain on their long-term 
oral antiplatelets after receiving cangrelor during PCI. The 
costs of GPIs use may be −4,705€ lower. There would also 
Figure 1 Three years distribution of the total, primary PCI and PCI population in 
whom antiplatelet therapy with oral P2Y12 inhibitors is not feasible or desirable, in 
Spain.
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be differences in the number and costs of clinical events 
between the scenario without cangrelor compared with the 
scenario with cangrelor in the hospital formulary (Table 
6). The costs of ischemic and bleeding events may repre-
sent 47,119€ and 2,500€ over three years, respectively. 
Greater differences may appear in the incidence of throm-
botic events compared to the incidence of bleeding epi-
sodes. The budget impact would be sensitive to the size of 
the population using GPIs (bail-out) and to the number of 
clinical events over three years (Figure 3). The cost of 
Table 4 Assumptions Considered in the Budget Impact Model (Base Case)
Epidemiology
A steady 2% growth of PCI population occurs over three years in Spain.23
Clinical
The same frequency of clinical events (ischemic and bleeding) occurs in clinical trials and in usual clinical practice.7
Use of antiplatelet drugs in the current and alternative scenario reflects usual medical practice.
TIMI is the bleeding scale used in practice.18,43
Comparators
The use of P2Y12 inhibitors is redistributed within the same target population size after the introduction of cangrelor in the hospital formulary.
The introduction of cangrelor in the market mostly influence the size of the population with ticagrelor and clopidogrel.
The use of oral P2Y12 prasugrel remains unchanged at 9% in the scenario with cangrelor in the market.
The use of GPIs (bail-out) slightly decreases with cangrelor in the hospital formulary.
Other assumptions
The cost of ischemic events (stent thrombosis, myocardial infarction or ischemia-driven revascularization) is the same.
The cost of bleedings (minor or major) is the same.
Costs remain unchanged over three years (time horizon).
The cost of death is 0€.
Abbreviations: GPIs, glycoprotein IIb-IIIa inhibitors; PCI, percutaneous coronary intervention: TIMI, thrombolysis in myocardial infarction.
Table 5 Budget Impact Results for Cangrelor Amongst PCI Patients in Whom Antiplatelet Therapy with Oral P2Y12 Inhibitors is Not 
Feasible or Desirable in Spain (Three-Year Time Horizon)
PCI Population in Whom Oral P2Y12 Inhibitors are Not Feasible or Desirable
Year 1 Year 2 Year 3
Target population, n* 760 2,280 4,180
Population with pre-treatment with P2Y12 inhibitors, n** 607 1,822 3,340
Uptake cangrelor, % 23.70 58.30 51.30
Total costs current scenario (without cangrelor) *** 273,725.00€ 821,174.00€ 1,505,485.00€
Costs of GPIs use 20,965.00€ 62,896.00€ 115,310.00€
Cost of pre-treatment with oral P2Y12 inhibitors before PCI 2,014.00€ 6,041.00€ 11,074.00€
Cost of oral P2Y12 inhibitors after PCI 1,232.00€ 3,695.00€ 6,773.00€
Costs of clinical events (ischemic) at 48h of PCI 241,582.00€ 724,746.00€ 1,328,700.00€
Costs of adverse events (bleedings) at 48h of PCI 7,932.00€ 23,797.00€ 43,628.00€
Total costs alternative scenario (with cangrelor) 323,969.00€ 1,193,374.00€ 2,104,757.00€
Costs of GPIs use 20,470.00€ 61,410.00€ 112,586.00€
Cost of pre-treatment with P2Y12 inhibitors before PCI 50,163.00€ 361,425.00€ 584,342.00€
Cost of oral P2Y12 inhibitors after PCI 1,232.00€ 3,695.00€ 6,773.00€
Costs of clinical events (ischemic) at 48h of PCI 243,838.00€ 742,319.00€ 1,355,990.00€
Costs of adverse events (bleedings) at 48h of PCI 8,266.00€ 24,525.00€ 45,066.00€
Budget impact (per year) 50,245.00€ 372,200.00€ 599,272.00€
Total budget impact for 3 years 1,021,717.00€
Notes: *Total population in whom oral P2Y12 inhibitors are not feasible or desirable. **Patients in whom antiplatelet treatment with oral P2Y12 inhibitors would be needed. 
***Total cost in the current and alternative scenario and the total budget impact for 3 years is highlighted in bold text in the table. 
Abbreviations: GPIs, glycoprotein IIb-IIIa inhibitors; PCI, percutaneous coronary intervention.
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clinical events or the percentage of usage of clopidogrel 
would have minor influence in the budget impact.
Discussion
The results of the present economic analysis demonstrate 
that the financial impact of introducing cangrelor into the 
drug formulary of hospital pharmacies for the adjunctive 
treatment of approximately 6,000 PCI patients in whom 
the use of oral P2Y12 inhibitors is not feasible or desirable, 
slightly exceeds one million € over three years, in Spain. 
Compared to the budget impact of adjunctive oral antipla-
telet drugs, it was reported that increasing by 5% to 10% 
the use of oral prasugrel only, or prasugrel and ticagrelor, 
versus clopidogrel in ACS patients undergoing PCI 
reached 239 million € to 252 million € over 3 years in 
Spain (2017 €).11
Likewise, two previous economic studies conducted in 
Spain (in 2010 and 2012, respectively) analyzed the cost 
implications of replacing clopidogrel by prasugrel or tica-
grelor in patients undergoing PCI.34,35 The first study 
anticipated a budget impact of 8,245 million € in 
one year if 5% of the patients treated with clopidogrel 
were given prasugrel instead.35 The second study showed 
a budget impact in the range of 63,000€ to 86,000€ per 
each avoided death due to thrombotic events after repla-
cing clopidogrel by ticagrelor, without considering bleed-
ing costs.34 Overall, these data revealed that an important 
financial effort was made to introduce the two potent oral 
P2Y12 inhibitors, prasugrel and ticagrelor, into the drug 
formulary in Spain. Introducing cangrelor into the formu-
lary of hospital pharmacies in Spain implies higher phar-
macological costs. However, compared to drug costs, 
revascularization procedures and length of hospital stay 
Figure 2 Pharmacological and clinical event costs before and after introducing cangrelor into the hospital formulary in Spain for managing PCI patients in whom oral P2Y12 
inhibitors are not feasible or desirable (three-year time horizon).
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are greater contributors of direct medical costs during the 
first year following an acute coronary event. They may 
reach up to one billon € in Spain.36
Taking into account the frame of the present analysis, 
meaning early PCI (<2 h)4,5 under clinical conditions in 
which the adjuvant antiplatelet treatment with oral P2Y12 
inhibitors may not be feasible or desirable, it should also be 
considered that the antiplatelet effect of crushed ticagrelor37 
and chewed prasugrel38 were also investigated as potential 
alternatives to improve their oral bioavailability. Although 
the results showed that time to maximum plasma concentra-
tion was shorter in the crushed ticagrelor group versus the 
integral tablets group, the median time of 2 h vs 4 h, respec-
tively, still represents the delayed onset of the ticagrelor 
antiplatelet effect.37 In line with these results, the recently 
published FABOLUS FASTER pharmacodynamic study 
compared the antiplatelet effect of chewed prasugrel vs 
a loading dose of integral prasugrel tablet and demonstrated 
that chewed prasugrel led to higher active metabolite con-
centration but not to a greater platelet aggregation 
inhibition.38 The results of these pharmacodynamic studies 
emphasize that even the faster oral P2Y12 alternatives may 
still not be desirable. In this context, cangrelor represents an 
affordable iv alternative for immediate P2Y12 inhibition.
The therapeutic value of cangrelor is well aligned to the 
expected for a highly effective antiplatelet strategy to be used 
in the acute setting of PCI.39,40 Antiplatelet drugs with 
a favorable benefit/risk profile are needed to improve the 
overall clinical and economic outcomes of PCI patients in 
Spain, including the reduction of the length of hospital stay 
and the decrease in the number of periprocedural clinical 
events.41 In this regard, cangrelor is an innovative iv antiplate-
let adjunctive strategy to guarantee an immediate, potent, and 
rapidly reversible effect in patients undergoing PCI, in whom 
an oral P2Y12 inhibition is not feasible or desirable.42
There are limitations in the present budget impact model 
that should be considered. Although all the inputs used in 
the analysis were taken from published registries, clinical 
trials and metanalysis and were further validated by external 
clinical experts, it was not always possible to identify the 
precise factors that matched the model definitions and 
represented the acute hospital setting of ACS, in Spain. 
For instance, PCI population growth and percentage distri-
butions for P2Y12 inhibitors usage may differ from the 
model assumptions in forthcoming years implying changes 
in the budget impact estimates. The same cost for both 
minor and major bleeding events were considered. As 
a consequence, bleeding costs may have been overesti-
mated. Likewise, other cost assumptions may further influ-
ence these results, both positively and negatively. Adverse 
events associated to GPIs were not modelled and may have 
influenced the budget impact results. Differences in cases 
characterization, studies design and patients’ representative-
ness amongst publications made data selection difficult to 
carry out. For this reason, assumptions were made to solve 
this lack of available evidence.
Table 6 Distribution of Clinical (Ischemic and Bleeding) Events 
Amongst PCI in Whom Antiplatelet Therapy with Oral P2Y12 
Inhibitors is Not Feasible or Desirable in the Scenarios without 
and with Cangrelor in the Hospital Formulary in Spain (Three- 
Year Time Horizon)
Year 1 Year 2 Year 3
Current scenario (without cangrelor)
Total number of ischaemic events at 48h of PCI (efficacy)
ST, n 4 11 20
MI, n 18 53 97
IDR, n 4 12 21
Cardiac death, n 2 6 12
Total number of bleedings, TIMI scale at 48h of PCI (safety)
Major, n 2 5 9
Minor, n 4 11 20
Alternative scenario (with cangrelor)
Total number ischaemic events at 48h of PCI (efficacy)
ST, n 4 10 19
MI, n 18 57 103
IDR, n 4 11 20
Cardiac death, n 2 6 10
Total number of bleedings, TIMI scale at 48h of PCI (safety)
Major, n 2 5 10
Minor, n 4 11 20
Difference in clinical events per year, current vs alternative 
scenarios
Ischemic events at 48h of PCI (efficacy)
ST 0 −1 −1
MI 0 +4 +6
IDR 0 −1 −1
Cardiac death 0 0 −2
Bleeding events at 48h of PCI (safety)
Major 0 0 +1
Minor 0 0 0
Abbreviations: IDR, ischemia-driven revascularization; MI, myocardial infarction; 
PCI, percutaneous coronary intervention; ST, stent thrombosis; TIMI, thrombolysis 
in myocardial infarction.
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Despite these limitations, this budget impact analysis 
provides an estimate of introducing a novel antiplatelet iv 
strategy for PCI patients in whom the use of oral P2Y12 
inhibitors is not feasible or desirable. Further research should 
focus on determining the most cost-effective scenarios for 
using cangrelor in the clinical practice.
Conclusions
Cangrelor represents an innovative iv strategy for the 
adjunctive antiplatelet therapy in PCI patients in whom an 
oral P2Y12 inhibition is not feasible or desirable. The eco-
nomic effort that would be needed to incorporate cangrelor 
into the hospital pharmacy formulary seems to be within 
reasonable margins in Spain, barely exceeding one million € 
over 3 years. However, further research with a more robust 
design is needed to confirm these findings.
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